Global Hepatitis B and C Diagnostics Market Size, Status, Research and Forecast 2019-2025

Published On: Jul 2019

Format: PDF

Publisher: QY Research

Pages: 102

Report ID: 3993

Hepatitis B diagnostic tests include HBV serologic tests, molecular deoxyribonucleic acid (DNA) tests, histology tests, and laboratory tests. HBV serologic tests involve the measurement of antigens and antibodies. Hepatitis C diagnostic tests include anti-HCV serologic test, HCV recombinant immunoblot assay (RIBA) antibody test, and HCV molecular ribonucleic acid (RNA) testing. Anti-HCV is the serologic test used for screening.
The increasing demand for molecular diagnostic of HBV (hepatitis B virus) and HCV (hepatitis C virus) infections is one of the primary drivers for the growth of this market. Molecular diagnosis simplifies sample preparation for high-volume testing and includes identification and profiling of causative agents of infection and the quantification of pathogens to monitor durability of therapy; thus, resulting in sales of around 60% of the overall molecular diagnosis market. Additionally, new companies are also focusing on the development of new products, which, in turn, is expected to change market dynamics for the diagnosis of HBV and HCV infections. For instance, Cepheid recently announced a quantitative test that offers on-demand molecular testing for confirmation of infection and monitoring of HCV and has obtained CE-IVD (in vitro diagnostics) status under the European Directive on in-vitro diagnostic medical devices, making it one of the leading platforms for molecular diagnosis.
Increasing incidence of HBV and HCV infections in the Americas will contribute to the growth of the diagnostic market. The Americas will dominate the market, accounting for half of the total market share by 2023. The recent increase in blood transfusion will result in the adoption of third-generation hepatitis C diagnostic tests like HCV enzyme immunoassay that contribute to the growth of the market in this region. Also, the implementation of biomarker-based POC (point-of-care) tests initiated by the government and non-profit organizations, is also expected to drive the market growth as the products are highly accessible and easy to use.
In 2018, the global Hepatitis B and C Diagnostics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Hepatitis B and C Diagnostics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Hepatitis B and C Diagnostics development in United States, Europe and China.

The key players covered in this study
Roche Diagnostics
Abbott
Siemens
Qiagen
Alere
bioMérieux
Cepheid
Chembio Diagnostics
DiaSorin
Enzo Life Sciences
Hologic
MedMira
OraSure Technologies
Quest Diagnostics
Quidel Corp
Randox Laboratories

Market segment by Type, the product can be split into
Hepatitis B
Hepatitis C

Market segment by Application, split into
Immunodiagnostics
Nucleic Acid Test (NAT)

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Hepatitis B and C Diagnostics status, future forecast, growth opportunity, key market and key players.
To present the Hepatitis B and C Diagnostics development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Hepatitis B and C Diagnostics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Hepatitis B and C Diagnostics Market Size Growth Rate by Type (2014-2025)
1.4.2 Hepatitis B
1.4.3 Hepatitis C
1.5 Market by Application
1.5.1 Global Hepatitis B and C Diagnostics Market Share by Application (2014-2025)
1.5.2 Immunodiagnostics
1.5.3 Nucleic Acid Test (NAT)
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Hepatitis B and C Diagnostics Market Size
2.2 Hepatitis B and C Diagnostics Growth Trends by Regions
2.2.1 Hepatitis B and C Diagnostics Market Size by Regions (2014-2025)
2.2.2 Hepatitis B and C Diagnostics Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Hepatitis B and C Diagnostics Market Size by Manufacturers
3.1.1 Global Hepatitis B and C Diagnostics Revenue by Manufacturers (2014-2019)
3.1.2 Global Hepatitis B and C Diagnostics Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Hepatitis B and C Diagnostics Market Concentration Ratio (CR5 and HHI)
3.2 Hepatitis B and C Diagnostics Key Players Head office and Area Served
3.3 Key Players Hepatitis B and C Diagnostics Product/Solution/Service
3.4 Date of Enter into Hepatitis B and C Diagnostics Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Hepatitis B and C Diagnostics Market Size by Type (2014-2019)
4.2 Global Hepatitis B and C Diagnostics Market Size by Application (2014-2019)

5 United States
5.1 United States Hepatitis B and C Diagnostics Market Size (2014-2019)
5.2 Hepatitis B and C Diagnostics Key Players in United States
5.3 United States Hepatitis B and C Diagnostics Market Size by Type
5.4 United States Hepatitis B and C Diagnostics Market Size by Application

6 Europe
6.1 Europe Hepatitis B and C Diagnostics Market Size (2014-2019)
6.2 Hepatitis B and C Diagnostics Key Players in Europe
6.3 Europe Hepatitis B and C Diagnostics Market Size by Type
6.4 Europe Hepatitis B and C Diagnostics Market Size by Application

7 China
7.1 China Hepatitis B and C Diagnostics Market Size (2014-2019)
7.2 Hepatitis B and C Diagnostics Key Players in China
7.3 China Hepatitis B and C Diagnostics Market Size by Type
7.4 China Hepatitis B and C Diagnostics Market Size by Application

8 Japan
8.1 Japan Hepatitis B and C Diagnostics Market Size (2014-2019)
8.2 Hepatitis B and C Diagnostics Key Players in Japan
8.3 Japan Hepatitis B and C Diagnostics Market Size by Type
8.4 Japan Hepatitis B and C Diagnostics Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Hepatitis B and C Diagnostics Market Size (2014-2019)
9.2 Hepatitis B and C Diagnostics Key Players in Southeast Asia
9.3 Southeast Asia Hepatitis B and C Diagnostics Market Size by Type
9.4 Southeast Asia Hepatitis B and C Diagnostics Market Size by Application

10 India
10.1 India Hepatitis B and C Diagnostics Market Size (2014-2019)
10.2 Hepatitis B and C Diagnostics Key Players in India
10.3 India Hepatitis B and C Diagnostics Market Size by Type
10.4 India Hepatitis B and C Diagnostics Market Size by Application

11 Central & South America
11.1 Central & South America Hepatitis B and C Diagnostics Market Size (2014-2019)
11.2 Hepatitis B and C Diagnostics Key Players in Central & South America
11.3 Central & South America Hepatitis B and C Diagnostics Market Size by Type
11.4 Central & South America Hepatitis B and C Diagnostics Market Size by Application

12 International Players Profiles
12.1 Roche Diagnostics
12.1.1 Roche Diagnostics Company Details
12.1.2 Company Description and Business Overview
12.1.3 Hepatitis B and C Diagnostics Introduction
12.1.4 Roche Diagnostics Revenue in Hepatitis B and C Diagnostics Business (2014-2019)
12.1.5 Roche Diagnostics Recent Development
12.2 Abbott
12.2.1 Abbott Company Details
12.2.2 Company Description and Business Overview
12.2.3 Hepatitis B and C Diagnostics Introduction
12.2.4 Abbott Revenue in Hepatitis B and C Diagnostics Business (2014-2019)
12.2.5 Abbott Recent Development
12.3 Siemens
12.3.1 Siemens Company Details
12.3.2 Company Description and Business Overview
12.3.3 Hepatitis B and C Diagnostics Introduction
12.3.4 Siemens Revenue in Hepatitis B and C Diagnostics Business (2014-2019)
12.3.5 Siemens Recent Development
12.4 Qiagen
12.4.1 Qiagen Company Details
12.4.2 Company Description and Business Overview
12.4.3 Hepatitis B and C Diagnostics Introduction
12.4.4 Qiagen Revenue in Hepatitis B and C Diagnostics Business (2014-2019)
12.4.5 Qiagen Recent Development
12.5 Alere
12.5.1 Alere Company Details
12.5.2 Company Description and Business Overview
12.5.3 Hepatitis B and C Diagnostics Introduction
12.5.4 Alere Revenue in Hepatitis B and C Diagnostics Business (2014-2019)
12.5.5 Alere Recent Development
12.6 bioMérieux
12.6.1 bioMérieux Company Details
12.6.2 Company Description and Business Overview
12.6.3 Hepatitis B and C Diagnostics Introduction
12.6.4 bioMérieux Revenue in Hepatitis B and C Diagnostics Business (2014-2019)
12.6.5 bioMérieux Recent Development
12.7 Cepheid
12.7.1 Cepheid Company Details
12.7.2 Company Description and Business Overview
12.7.3 Hepatitis B and C Diagnostics Introduction
12.7.4 Cepheid Revenue in Hepatitis B and C Diagnostics Business (2014-2019)
12.7.5 Cepheid Recent Development
12.8 Chembio Diagnostics
12.8.1 Chembio Diagnostics Company Details
12.8.2 Company Description and Business Overview
12.8.3 Hepatitis B and C Diagnostics Introduction
12.8.4 Chembio Diagnostics Revenue in Hepatitis B and C Diagnostics Business (2014-2019)
12.8.5 Chembio Diagnostics Recent Development
12.9 DiaSorin
12.9.1 DiaSorin Company Details
12.9.2 Company Description and Business Overview
12.9.3 Hepatitis B and C Diagnostics Introduction
12.9.4 DiaSorin Revenue in Hepatitis B and C Diagnostics Business (2014-2019)
12.9.5 DiaSorin Recent Development
12.10 Enzo Life Sciences
12.10.1 Enzo Life Sciences Company Details
12.10.2 Company Description and Business Overview
12.10.3 Hepatitis B and C Diagnostics Introduction
12.10.4 Enzo Life Sciences Revenue in Hepatitis B and C Diagnostics Business (2014-2019)
12.10.5 Enzo Life Sciences Recent Development
12.11 Hologic
12.12 MedMira
12.13 OraSure Technologies
12.14 Quest Diagnostics
12.15 Quidel Corp
12.16 Randox Laboratories

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details